

Isentress® (raltegravir) - Expanded indication

- On November 22, 2017, the FDA approved Merck's <u>Isentress (raltegravir)</u> in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing ≥ 2 kg.
 - Previously, in the pediatric population, Isentress was indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients 4 weeks of age and older
 - Isentress is not recommended in pre-term neonates or in pediatric patients weighing < 2 kg.
- Isentress is also indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients.
 - Raltegravir is also available as <u>Isentress[®] HD</u>. Isentress HD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients, and in pediatric patients weighing ≥ 40 kg.
- The safety and pharmacokinetics of Isentress for oral suspension were evaluated in 42 full-term HIV-1 exposed neonates at high risk of acquiring HIV-1 infection. HIV-1 status was assessed at birth, week 6, and week 24. All patients were HIV-1 negative at completion of the study.
- The safety profile of Isentress in full-term HIV-1 exposed neonates was comparable to that observed in adults.
- In pediatric patients from birth to 4 weeks of age weighing ≥ 2 kg, the recommended dosage of Isentress oral suspension is based on body weight and given once or twice daily.

Body weight (kg)	Volume (dose) of oral suspension
Birth to 1 week old – once daily dosing*	
2 kg to < 3 kg	0.4 mL (4 mg) once daily
3 kg to < 4 kg	0.5 mL (5 mg) once daily
4 kg to < 5 kg	0.7 mL (7 mg) once daily
1 week to 4 weeks old – twice daily dosing [†]	
2 kg to < 3 kg	0.8 mL (8 mg) twice daily
3 kg to < 4 kg	1 mL (10 mg) twice daily
4 kg to < 5 kg	1.5 mL (15 mg) twice daily

^{*} Dosing recommendations are based on approximately 1.5 mg/kg/dose

 For the recommended dosage of Isentress in other patient populations, including adults and pediatric patients ≥ 4 weeks of age, please refer to the drug label.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.

^T Dosing recommendations are based on approximately 3 mg/kg/dose